Pharmaceutics · 2022 · 25 citations · 40 references
PharmacyPharmaceuticsPharmacologyDrug DeliveryNanoparticle Drug DeliveryOcular Drug DeliveryDiabetic RetinopathyNanomaterials For Drug DeliveryNanomedicineNanoparticle DesignOcular NanocarriersOcular Targeted DeliveryAnti-vegf Ocular TherapyDendrimer-based DeliveryDendrimersDrug Delivery To The EyeDrug Delivery To The RetinaIntravitreal Anti-vascular Endothelial Growth Factor TherapyNanoparticlesVascular Endothelial Growth Factor Inhibition
Ruboxistaurin (RBX) is an anti-vascular endothelial growth factor (anti-VEGF) agent that is used in the treatment of diabetic retinopathy and is mainly given intravitreally. To provide a safe and effective method for RBX administration, this study was designed to develop RBX nanoparticles using polyamidoamine (PAMAM) dendrimer generation 5 for the treatment of diabetic retinopathy. Drug loading efficiency, and in vitro release of proposed complexes of RBX: PAMAM dendrimers were determined and the complexation ratio that showed the highest possible loading efficiency was selected. The drug loading efficiency (%) of 1:1, 2.5:1, and 5:1 complexes was 89.2%, 96.4%, and 97.6%, respectively. Loading capacities of 1:1, 2.5:1, and 5:1 complexes were 1.6%, 4.0%, and 7.2% respectively. In comparison, the 5:1 complex showed the best results in the aforementioned measurements. The in vitro release studies showed that in 8 h, the RBX release from 1:1, 2.5:1, and 5:1 complexes was 37.5%, 35.9%, and 77.0%, respectively. In particular, 5:1 complex showed the highest drug release. In addition, particle size measurements showed that the diameter of empty PAMAM dendrimers was 214.9 ± 8.5 nm, whereas the diameters of loaded PAMAM dendrimers in 1:1, 2.5:1, 5:1 complexes were found to be 461.0 ± 6.4, 482.4 ± 12.5, and 420.0 ± 7.1 nm, respectively. Polydispersity index (PDI) showed that there were no significant changes in the PDI between the free and loaded PAMAM dendrimers. The zeta potential measurements showed that the free and loaded nanoparticles possessed neutral charges due to the presence of anionic and cationic terminal structures. Furthermore, the safety of this formulation was apparent on the viability of the MIO-M1 cell lines. This nanoformulation will improve the therapeutic outcomes of anti-VEGF therapy and the bioavailability of RBX to prevent vision loss in patients with diabetic retinopathy.
40
Use of an Aqueous Soluble Tetrazolium/Formazan Assay for Cell Growth Assays in Culture
Ann H. Cory, Terence C. Owen, J. A. Barltrop et al. · Cancer Communications · 1991 · 1.5K citations
Jeffrey D. Clogston, Anil K. Patri · Methods in molecular biology · 2010 · 1.3K citations
Ocular drug delivery systems: An overview
Ashaben Patel · World Journal of Pharmacology · 2013 · 861 citations · Full text